Mold-Tek Packaging Limited (533080) Earnings Call Transcript
February 9, 2026
Earnings Call Speaker Segments
Good day, ladies and gentlemen, and welcome to the Q3FY26 earnings conference call for Moltech Packaging Limited, hosted by MK Global Financial Services Limited. As a reminder, every participant line will remain in listen-only mode, and you'll have a chance to ask questions once the presentation wraps up. If you need help at any point during the call, just signal an operator by pressing Star then zero on your touchtone phone. Please be aware that this conference is being recorded. I'll now hand things over to Mr. Mohit Dodeja. Thank you. Over to you, sir.
Yeah. Hello. Good evening, everyone. I'd like to welcome Mr. Lakshman Rao, our chairman and managing director, and thank him for giving us this opportunity. I'll now turn the call over to him for the opening remarks. Over to you, sir.
Good afternoon, everyone. Thanks so much for being on our Q3 results call. You may have seen the results already — they were published on BSE and NSE. Our EBITDA is up by nearly 20% over the nine months versus the same nine months a year earlier, and sales in value terms have risen roughly 12%. In Q3 to Q3, though, sales volumes grew 6% and EBITDA also increased 14%. As you know, Q3 has traditionally been our weakest quarter each year, but things began improving right from January. We saw more than double digit growth in January — this January alone — and the order book for February looks quite strong as well. So going forward, I think we'll return to a normal level of 12% to 15% volume growth, which is achievable in Q2 and Q1, generally Q4 and Q1. The next six months are our busy season, so things will start looking up, and we hope to catch up with the busy demand, since we're well geared up on our side. As I said in my press release, we've largely finished consolidating the manufacturing units in Hyderabad, where we used to have five units and now it will be just two units.
Units one and ten. The printing unit now has space there too. Unit four — a small facility in one of the Sultanpur Hyderabad blocks that mostly serves Asian pains — has likewise been shifted to Sultanpur B block. So from 5 units, we'll be down to just 2, with 2 already absorbed. Unit 4, though, gets absorbed starting March. That should show up as improved operational efficiencies, better cost controls, and smoother direction and movement of goods as well as personnel. Those effects ought to become visible, hopefully, from next quarter. And there's another encouraging sign. Wipe generation, with whom we've signed a MoU to develop their product patents and ideas here in India for projects and other applications — we've gotten the first two component drawings, designs are underway, and pilot molds should be ready by the close of this month. One of those will be done by the close of February, another by March, and commercial feasibility gets tested after that. Hopefully, by the close of Q1, we'll have commercial moulds turning out these components not just for European markets — under our MoU with vibe, these products can be sold in the Indian market as well.
That's one more development, and it carries over into Pharma. At this point, over 25 clients have completed their audits of our facilities and received clearance to produce. That said, under half of those clients have begun commercial pickup, while the remainder will kick off over the next few months, which secures solid volume growth for Pharma in the quarters ahead too. That's the forward-looking picture, and I believe further detail can be covered during the Q&A. I'll hand things back to Anushka to set up the question and answer portion.
Thanks. We’re moving into the Q&A portion now. If you’d like to ask something, press STAR then one on your touch-tone phone. Should you want to drop out of the queue, press STAR and two; we also ask that participants use handsets when posing a question. Ladies and gentlemen, we’ll pause briefly while the queue is put together. Our first question comes from Deepak with Nirmal Bank Institutional Equities. Go ahead, please.
Hi there, this is Audible speaking.
Correct.
Alright, hello, and thanks for the chance to ask. Sir, my first question concerns the MOU we signed with Light Generation. Could you share a bit about what kind of product it is, so we understand it better? And is there anything comparable on our side, say with the new products where leakage matters a great deal — for instance, in how safely we handle liquids, or even when it comes to dust particles? So if you could expand a little on what the product actually is, and then, second, on the MoU with Swiggy: do you view that type of product as one where churn would be materially higher than the churn we see, say, in the other food categories? Those are my first two questions. Yeah.
As for why I can’t share product details at this point—under the MOU, we need to develop the molds and establish product quality before any announcement is made. That said, I can tell you this product also has applications in India within our client segments. It’s adding quite a bit of value in terms of application and user friendliness. So once these products are established and developed—probably by April or May, when we discuss the Q4 results—I’ll probably be in a position to shed better light. But I can tell you these products are extremely user friendly, add high value, and they’re patented by Vibe, and we hold the right to use the patent here in India, and we see applications that are very much welcomed here as well in Indian industry. However, I won’t claim this is worth hundreds of crores of value. But certainly it will be tens of crores, and over the next one year we can see its potential.
Understood, sir. Second, on the total volume figure: at the start of the year, we thought we could hit somewhere around 43,000 to 45,000 in nine months. We're at, say, 31,000 now. So looking at Q4, even with just a slight double-digit quarter, is it fair for ENA to say you'd land at the low end of that 43 to 45 guided range — closer to the lower threshold? Or do you think, since you stressed the momentum is strong from the start of the year, we could get a somewhat better quarter than expected? And could Q4 volume come in relatively better than what we saw in Q1?
Most likely, Q4 will be on par with Q1. We couldn't exceed it. Q1 was quite robust. In that quarter, we had 11,400 tons of production and sales. Hopefully we'll equal that and bring it to 42.5 thousand, versus the 44, 45 we originally projected. Even so, that will still be roughly 11% volume growth, a bit under what I anticipated because of extended rainfall in the first—especially in the second quarter.
Understood, sir. So on the pharma side, if traction stays strong — and in only nine months we've already done, say, 25 crore — I just want to get a handle on the Q3 seasonality pattern we have. Does that also apply to pharma? And given that in 4Q we ought to return to that same normal run rate of 10 crore, 11 crore that you had. Again, given the 35 crore sort of target we had earlier, that should be reached.
Yes, we will hit 35 crores. Although across the first three quarters we're sitting at roughly 25 crores. As you rightly pointed out, Q3 is a bit of a dampener for pharma too. This time it's slightly more because of uncertainty over tariffs from the US. There was some uncertainty about volume pickups from the pharma industry. But I think now that it's been clarified, it might start picking up really well. And whether it's done or not. For the Indian market as well, the winter months are low for EV tubes, which are the major segment that took a hit in Q3. But given the strong order book, from the middle of January onwards we feel we may be able to cross or at least reach the figure of 35 crores for the full year. And for next year we've kept a target of 50 to 5055 crores. That is again a 40 to 45% growth on the current year number we've taken. And that will add sizeably to the bottom line as well, because we are now well above the breakeven point.
Understood, sir — one final question before I move on to the news side. If you could comment: on the volume side, we've been seeing a steady decline. We're aware this is an area where we've encountered some challenges. But is there any additional indication — perhaps from further discussions we've had with clients — of volumes rising somewhat on the higher side, or of improvement here? That's my last question. Thank you for the opportunity, sir.
Yeah, with lubricants we're seeing a decline — actually a considerable one. Even in the quarter we just closed, we finished with a minus 10% volume growth in lubricant. The basic reason is that we aren't actively taking part in that very low grade lubricant market of DEF loops, which are mostly urea based lubricants. Those segments have turned into a very low cost product range, and Maltech isn't inclined to hold capacity there. So that's one reason, and the general trend in lubricant this year is downward. I don't know much about how the lubricant company per se has performed, but. Because of five to six months of. Extended monsoon this year, the movement of. Goods and therefore lube consumption has fallen off. That's the news I have. So while clients like Castrol — we still have growth there, positive growth — but. There are clients where we've seen a dip in their volumes. So that reason may be universal. Another reason, as I said, is that we. Are letting go of some of the low end loop opportunities.
Thanks.
Thanks. We’ll go now to Shankar from Iraya Capital on the line. Go ahead, please.
Hi there.
Hello, sir, and thanks for taking my question. You've given us some color on how growth trends are shaping up. Could you share a bit more detail — you mentioned 11% volume growth, but what kind of sales growth should we expect in Q4? And if you're in a position to do so, could you also share a further outlook for next year? That's my first question.
Right. We might wrap up this year at 870 crores in top-line revenue. So going into next year, we definitely have a goal of crossing a thousand crores — that's capital. I mean, internally the aim is to comfortably get past a thousand crores. That works out to roughly 13, 14% volume growth. And judging by how aditya Birla Group ABG has been trending — they grew about 21% in Q3 — we're confident that with their Mahad plant also running at full capacity, we'll keep seeing solid double-digit growth in Grassim. And now that the RCP issues with Asian Paints are resolved, we've also started seeing Asian Paints volumes pick up, beginning in January. Under the RCP they want 40 to 50% recycled plastic in their paints, because of the government's statutory obligation. So we've successfully developed that formula and were able to begin supplies in December, and from January onward it will give them confidence that Amaltech will be a pioneer — or at least one of the first pail manufacturers — to meet statutory compliance. So with that done, we hope Asian Paints, which is at hardly 3, 4% volume growth, can move into double digits in the next financial year, which will be a big pull for the rest of our other segments — all of which are definitely in double digits, healthy double digits.
We're confident about next year as well. Our target is 12 to 15% volume growth. And once we get there, we'll likely pass the 1000 crores top line benchmark. And this year's EBITDA — as you know, for the nine months it's 125 crores, and hopefully we close at around 170 crores, that's the target for the current year, up from 144 last year. So that's again a 2022 percent EBITDA growth. And next year we'll comfortably cross 200, or maybe 215 — 200 to 210 crore IBITA.
Got it, and thanks for laying all that out so thoroughly. Now, moving from EBITDA down to PAT, could you give us some color on the growth — specifically, where do you expect that operating leverage to come through as you go from the EBITDA line to the PAT line? For instance—
Yeah, over these nine months, we have reported an 18% rise in PAT, from 44.3 crores in the same nine months last year to 52.25. Earnings per share has likewise increased, from 13.3 to 15.75. So at the PAT level we have healthy growth of roughly 18%, and hopefully next year it should reach 20% growth. That covers the nine-month period. Hopefully, for the full year, we will be in a position to land somewhere around 70 to 75 crores — 73 to 75 crores PAT, up from 60 last year. That works out to about 20% PAT growth, similar to our EBITDA growth. Similar growth is what we can anticipate for the next financial year as well.
Got it. So what you're saying is that at the PAT level, we can expect similar 20% growth for this year and also for next year?
Correct.
Understood. Could you give us some detail on the capital expenditures you expect to wrap up this year? Has your earlier capex guidance shifted at all, and do you have any estimate for next year?
Yes, we’ve completed our budgeting for the next financial year during the past month, and the good news is that Capex will drop considerably next year, since all greenfield projects are more or less finished apart from a little bit of work at bahad. So next year the major expansion will be in Pharma, where we expect to spend at least around 25 crores, and we may enter into a couple of new products like eyedroppers and maybe nasal droppers toward the end of the year. Nasal sprays. So these two products — idroppers is already in a pilot model development stage, but the project will be out only in the second half of 26:27. And toward the end of the year we hope to enter into Nafal sprays based on our market research, if there is a positive demand gap. But for ophthalmic we are definitely going ahead. Pilot mounts are already under development, and as we go forward Pharma will at least keep growing at least around 30% thereafter — after we hit 5055 crores next year, thereafter we have a target of 30 to 35% volume growth coming from Pharma — and the very heartening thing is that the majority of our clients who have started buying commercial are very happy with our quality and timely supplies, and a couple of them are even asking us to set up warehouses near their plant to enhance our business.
So because of these trends, I have a great deal of confidence that within the next 2 to 3 years, we can become a fairly significant player in Pharma.
Got it. Could you say the capex figure in rupees once more?
Regarding capex, apologies — I omitted this earlier: last year's capex came to 140 crores, this year it should land near 120 crores, and for next year the target sits at 80 to 85 crores.
This year's number will land at 140, and next year it comes in at 82.
No, no, no. Last year it was 140; this year it's closing at roughly 120, and the target for next year is 80 to 85 crores.
Got it. Thanks, sir. With that, I’ll hand things back to the Q and A.
Thank you. The next question comes from Abhishek Navalgun at Centrum Broking. Please go ahead.
Hello there, sir, and thank you for taking my question. Regarding ABG in paints, on the previous earnings call you said that, if I recall correctly, in 1 inch we had achieved volumes of roughly 2,900 tons, which is broadly 30% of total paints volume, and you guided for about 6,500 tons by the end of the year — I mean the full-year figure. So where do we stand after nine months? What is the number, broadly in 3Q, since you mentioned ABG growth of some 21% this quarter — but in tonnage terms, where are we now?
So ABG came in at roughly 1480 tons for this quarter, and to date we're at about 4400 tons. Our hope is to reach the 6000 mark by the close of this year.
Sure. And regarding that 10,000 tons of capacity we brought up in connection with ABG — does that figure include the Mahad facility as well, or does it cover only the two that already exist?
And that covers Mahar as well.
And Mahar as well. Right, okay.
Right, so this year we may only be using 60 of that capacity, and we hope that from next year onward it will be about 70.
Yeah, yeah. And because we’re shifting ABG over to Mahad, do we have — I mean, has Asian Paints given us any signal on that, since you brought up the RCP matter? But beyond that, I mean, the Satara plant’s volume was fairly underused for a good while before this. So would you expect the ramp-up from Asian Paints to be considerably stronger perhaps in the quarters ahead, once we relocate the ABG production there?
So yeah, after that RCP problem got sorted out, the figures began climbing, and we were able to put together a recipe that adopts 40% RCEP, which is a statutory compliance requirement from the government. Since then, we're seeing those numbers rise, and we're hoping to achieve double-digit growth in Asian prints over the coming year.
Absolutely. Is there any chance to pick up market share in that area? Since you mentioned that yours is the only company that has cracked that.
No, no, no — that isn't necessarily the case. The other companies will be working out that same formula at the same time, since the suppliers will obviously approach every one of the manufacturers. So it'll be a couple of weeks, give or take. That means it won't really be much of an edge. But once this particular step has been completed, we've been — we are confident that we'll recover our previous percentage.
Alright. And broadly speaking, out of that 8085 crore of capex, how much would be for Mahar?
No, Mahad is barely anything at this point because those machines are already being installed at Satara. So what's going on there? It's just the shed plus auxiliary equipment worth around 5 crores at most. But then there are the other plants — the tool room itself. Replacing moulds alone runs about 20, 25 crores each year. And injection molding machines worth roughly 9 crores are planned across all the plants combined. Especially for the north plant where we are, since we're seeing good traction for our thin wall and Q packs. So that's what's raising our confidence to capture the north market. So there's an injection molding capacity enhancement in Panipat — not for ABG but mainly for the sake of Q packs and food and FMCG products. And around 25 to 30 crores will go toward Pharma. That's why next year's Capex could be kept within 80 to 85 crores.
And here's my final question. You brought up the Panipat FNF facility, so where do things stand with client engagement there? Have any clients been finalized for it yet?
Right, right, not a single one. Already, at least 8 to 10 clients have begun purchasing from us. And during this season, we expect that figure to rise to 25 to 30 clients, counting Qpack and Tindal together. And we anticipate those numbers will double in the season ahead.
Are there any categories you'd want to call out, if not names?
Every one of those categories. Whether it's confectionery, yogurts, ice creams, protein powder, edible oils, cashews, basmati, rice such as Q PEC — as in the Q PEC case — and there's ghee as well. We're bringing in all of these features, beginning with 6 ThinWal products right away, and another 6 by June, July, for the festival season. So that gives us 24 molds — meaning 12 sets running in the north by June, versus 4 sets at present. That's going to be a very large boost in food and FMCG for that segment, I expect. We're already seeing a really strong trend in QPAC sales, which got established 6, 7 months back. And as all of you know, Pinwell only began in September, October. So that one is picking up too, and we anticipate a solid improvement in the season ahead.
So the seasonality factor is going to be somewhat less, starting with Panipat FNS.
Not really. Q3 is still going to be our weakest period, I mean the least busy season, since paint usage, you name it, along with sweets and ice creams, all decline during winter. So Q3 typically remains our softest quarter. The next softest would be Q2, though this year it came in somewhat worse than earlier growth rates, which was due to extended range. Apart from that, Q2 would also be reasonably good. And Q3 is always the weakest quarter. That's behind us now. So hopefully, over the next three quarters we'll see solid volume. Guys.
Right, my apologies. Where Sultanpur is concerned, capacity utilization for FNS overall, we'd put that at 50, 60%, or below.
It's roughly 60 at this point, and it will rise from here.
Understood.
Right, but that figure needs to rise. Since the entire mission has been set up at a single site, there will be, you know, flexibility when certain machines sit idle — moulds can be mounted and other products made. So this provides considerable flexibility. And improved capacity utilization at Sultanpur.
Of course. Many thanks, and best wishes to you.
Appreciate it.
Thanks. We’ll take the next question from Pratyush Damani, an individual investor, who is on the line. Please go ahead.
Hi there.
Yeah, yeah,
Yeah. Thanks for giving me the chance. Just this one question. After every greenfield plant is up and all the factories are running, what would peak revenue potential be?
What's the peak level? With the missionary we have now and the plant itself, we can hit 1,200. The issue is that capacity utilization won't stay steady past 75%. Usually once you go beyond 75%–80%, you start getting mismatches between jars and caps. And in injection molding, anything over 75 is typically excellent. So I can say confidently that with the machines in place today, a thousand crores is achievable, and we're adding 21 more machines over the next three months and in the first six months of next financial year. That will contribute another 10 to 12% of capacity. Which means up to 1,150 to 1,200 crores. You can easily say 1,200 crores is possible with the existing and planned missions.
Okay, but so, like.
Apologies,
Yeah, injection molding — my apologies. Oh, hi there.
Yeah.
Right. You said roughly 75% plus is a really solid figure for injection molding. So I just want to get a sense of what kind of difficulty you run into — or what manufacturers run into — when trying to scale UP utility past 75 and injection molding.
Right. So what ends up happening is that the product mix isn’t going to line up perfectly with the capacities of your machinery. Jars and lids aren’t fully interchangeable. It isn’t viable to build a machine that runs both lids and jars. You can do it, but it’s costly and it won’t deliver the yield. So at times you might need to run a smaller component on a larger machine. As a result, capacity utilization will effectively drop. So that’s the reason anything above 75% for injection molecular capacity is regarded as good. And on top of that, you don’t use a machine’s full capacity. Take a machine rated to produce a 1200 gram component — you might run anywhere from 700 to 1200. So in effect your output volume won’t match your capacity. And sometimes the mould’s width or the depth of the moulded component differs. Then you have to use a larger machine, but your productivity comes out lower. So all of this means that in injection molding capacity utilization, anything above 75% is a very good outcome.
And when it comes to pharma, what utilization or capacity level would you consider ideal?
Same thing applies there as well. Injection molding equipment is used too, along with IBM machines. IBM refers to a blow molding machine. You run into comparable constraints there also. So a utilization rate of roughly 75% is considered solid.
All right, that's great. Thanks so much.
Thanks. Our next question comes from Akshay with Canada Mutual Fund. Go ahead.
Yes, sir. Thanks for giving me the chance to ask just one question. It's about the movie we've signed with Suzee. Could you talk a bit more about that? For instance, what incremental opportunity does it give us from here? And what type of margins can we expect going forward? Would they be, say, FNS-type margins, or would they be more like a paint margin?
Which one are you referring to? Vibe. Pardon?
Regarding Swiggy, sir — that's the Swiggy MOU we've completed.
Oh, Swiggy. Swiggy’s margins will be comparable to the ones we see in food and FMCG. Essentially, they purchase restaurant packs and food packs for the brands they promote. So they preferred — they positioned us as a preferred vendor for packaging products. As a result, they’ll be directing their restaurants and partners to purchase packs from Maltech. So we’ve been chosen as a preferred vendor for 3G restaurants. That will be comparable to our restaurant packs, which is food and FMCG. EBITDA, which comes to around 70 to 80 rupees per kg.
And whatever volume estimate or assumptions you might have regarding that roughly 100 tons for the coming year.
Looking ahead to next year, our plan and hope is to achieve volume growth of roughly 12 to 14% once more. That is the reason, starting from 870 crores, we are hoping to go past the thousand crore benchmark.
Sure, I was thinking more on Swiggy's side. For instance, how much extra volume could Swiggy bring in?
Well, regarding Swiggy — I really can't give you much right now, since the memorandum of understanding was signed only very recently. They still need to make the announcement public, and a number of the restaurants have yet to be approached; it will essentially function as one additional client. My sense is that it won't amount to a very large increment unless we watch how it performs over the coming couple of quarters. I'm not in a position to comment on it, though the reach is going to be quite substantial, and this will let us connect with an expanding number of restaurants and food delivery partners at a faster pace. So we'll have to wait and see. It was only finalized a month back — 15, 20 days ago.
All right, I really appreciate it.
Thanks. Our following question comes from Shiv, an individual investor. Kindly unmute yourself before speaking. We'll move on to the next participant. We now take a question from Amit Khetan Floung of Lipham Capital. Go ahead.
Hello sir, thanks for taking my question. Could you — you mentioned the drop in the lubricant segment. How much of that would you say is cyclical and ought to recover next year? How should we think about volumes in the lubricant segment for FY27?
Actually, there's a point I overlooked when I gave that answer, and I'd like to add it now. One factor behind the decline in our loops segment is that we lost the bpcl tender. The BPCL tender wrapped up last year, and this year it didn't go our way. So that's one of the reasons we're seeing a decline in loop numbers, particularly this quarter. Up until the second quarter of last year — a few months back, I mean — that tender had been completed, and we weren't able to secure it for the current period. That's one factor in the loop drop. Still, I think across the full nine months, the decline isn't as steep as 10% — it's somewhere around 6, 7%, I believe. So hopefully next year we should come back and at least recover this loss, because we added weed all recently and they've started picking up volumes over the last couple of months, and it may not be as big as bpcl, but to some extent it can fill up the gap.
Got it. Could you speak a bit about how intense the competition is overall, and particularly within the food segment?
As I told you a couple of quarters back, there's now competitive activity in the IML segment. Still, thanks to our range of robos, our broad product lineup, and supply from multiple locations, we're positioned to keep most of our clients and even bring on several more this year. Last year we dealt with a printing capacity shortage, and that's now fully resolved. We added a good amount of printing and lamination capacity, which is proving useful and lets us deliver goods on time — that in turn has rebuilt confidence among even smaller and mid-sized companies, and growth is back in the mid teens. So going forward, with north coming into the picture and production at full swing, we'll be sure of mid-teen growth in food and FMCG. Meanwhile QPAC should keep growing at around 25 to 2030%. The reason is basically that the court cases we filed against competitors copying our patented design are paying off. And recently a high court bench issued a ruling in our favor, stopping three competitors who infringed our patented model.
Got it. And one last thing, if possible — it would be really useful if you could tell us the EBITDA per kg across the various segments. Just roughly.
From what I’ve been saying, for paint and pails and even Q. Packs it comes to roughly 30 to 35 rupees, while for food and FMCG it’s nearer 70 to 80 rupees. And for pharma it runs about 120 to 140, depending on the product range.
And for lubricant, that figure ought to come in above 30 to 35. Right.
A bit better than paints.
Alright, thank you — and as always.
Thanks.
Thanks. We’ll go ahead and take the next question from Chirag at Keynote Capital. Please go ahead.
Thanks for taking my question. First thing I want to ask about is the paint segments. For paint segment X, what volume growth should we expect?
The total growth came in at 10.3%. Within that, ABG by itself accounted for roughly 21%. That works out to around 250 tons. So, out of the total, ABG supplied 21% of the 50%.
Could you share what the volume for ABG was during the prior year?
Yeah, ABG is around 4,800. So 250 works out to roughly 5% of that 10% growth. About 5% to 5.5% of the growth has come from ABG. The rest comes from Asian Paints and the others.
The next question ties into that same topic. As for the RCP that would be incorporated into our raw material, will it cause EBITDA per KV in the paint segment to go down?
No. What's going to happen is that the RCP gets bought at a slightly lower price, and that same benefit gets passed along to the client. So there won't be any impact on our EBITDA whatsoever.
So right now, RTP is available at a price below that of raw materials.
Yes, definitely — at minimum, it's 10% to 15% less expensive. That's among the reasons we weren't as competitive, since we couldn't make effective use of 40%. With the new recipe, we're now able to do so.
Understood, fair enough, sir. My next question concerns the food and FMCA segment. I just wanted to get some clarity regarding the situation once the printing press came into play — once that printing capacity came into the picture last quarter — what exactly has held us back from growing at more than 15% to 20% in this particular quarter?
This time, food and FMCG grew roughly 11%, and bulk packs were up 54%. Combined, that comes to close to around 12% volume growth. QPAC, though, grew 25%. Food and FMCG also had a tepid Q3, but Q4 already looks pretty strong — in January we saw growth above 17% to 18%. Looking ahead, the season for ice creams and yogurts begins. Summer picks up from March onward. So starting in February, we expect thin wall sales to take off.
But I believe there's a bit of a question about the figures you mentioned—the QPAT growth came in at roughly 34% for the quarter. That's year over year. You have
For the quarter. You're speaking. What I'm referring to is 9 months.
Alright, that's on me. Sorry about that. Understood, sir. Understood. The following question concerns the labor law expense you factored into employee benefit. Was the full amount booked within this quarter, or will it arrive as an incremental cost over the coming quarters?
No, those initial employee costs have already been absorbed. Nothing additional is coming. It will be — yeah, that's already been taken.
Looking ahead, what we're anticipating — is it fair for me to expect that employee costs will be lower going forward? Lower, relatively speaking, than what we saw this quarter?
Yeah, it might be somewhat lower by comparison, since this quarter took in a bit of extra provisions from the two quarters before. So as we move ahead, it could edge down slightly.
That's reasonable. And just to get a clearer picture — we've signed an MOU with Sriki. Typically, plastic containers of that kind would need a substantial volume coming from the client's process. So I just wanted to check whether, within this MA, there have been any discussions where they're asking you to install some kind of dedicated machinery in particular regions of India.
At the present level, it's also not very clear to them how volumes will pick up. Perhaps later, once volumes genuinely rise. Our north plant and our west plant also have the capability to make thinwal products, and what they'll mainly be is restaurant packs. And in that, we're actually launching some additional variants in this March April. So probably as their volumes increase and if they truly want capacity, we now have plants across India, so extra capacity or mounts can be added, and production can be done effectively from those locations. But I think I'd wait a quarter before commenting on this.
Alright, one final question from me. In the oil segment, we historically handled annual volumes of roughly 9,500 to 10,000 empty current. When I look at the run rate, which sits near 1800, it has fallen considerably from those levels—by almost 7000 to 8000. So.
Sorry, the 9500 you mentioned — what is that?
In the past, our oil business had an annual run rate in NT of roughly 9,000 to 10,000. That means a quarterly run rate of 2,400 to 2,500.
Oh, you're talking about the edible oil piece of Cube Axial.
No, no, sir. The oil — the one that's included in the lubes, the lubes one.
Every one of those loops you mentioned — got it.
Yeah, yeah.
So at the moment, that figure is on a quarterly basis. In the quarter we're in right now, we've got 18 tons.
Yeah.
So that works out to roughly 7,000 — in nine months we've already done 6,900 tons.
So the run rate was previously at a certain level. After implementing DPC in Q2, what run rate should we anticipate? It should be around 2,000. So for the coming year, we'd be handling roughly 8,000 volumes from Lubes.
Yeah, for loops we’ll land at roughly 8,000 tons. That’s it.
Understood, understood. This is the final question. Are we — are we — seeing volumes pick up from X ABG within the paint segments at a high single-digit to low double-digit rate at this point?
Starting from just the last month, I’d say we’re seeing solid figures from Asian Paints — above 10%. With Badger and Naralac, growth is maybe in the 5% to 6% range. That said, Badger has signaled they might shift into some of the IML packs. If they go ahead with that, then together with them we could also be looking at double-digit growth.
I appreciate it very much, sir. That's all I have to share.
Thanks. We’ll take the next question from Shanskar at Miraya Capital. Go ahead.
Hello there. Thanks, sir, for giving me the chance to ask again. So you mentioned we lost a BPCL tender this year. Could you point to any specific cause for that? Was it pricing, or was there some other reason?
Yes, price is the sole factor there. We simply aren't willing to drop beneath a particular profitability and pricing threshold. There may, however, be a few aggressive bidders who were looking to come in at a lower price. That's the reason.
So, are we seeing the same level of competition in other tenders and contracts from other companies?
No, it's just BCS, since those are government tenders. And as of today, our government lubricant sales are more or less at zero.
It's not just the Indian aisle either—other lube oil companies aren't purchasing from us. None of them are. Hpcl, bbcl,
BPCL was the final one to be divested. We divested it. And in fact, we might begin bringing on an additional private-sector vendor. In the previous year, we brought in Vidal. This year, one more client is at the final stage. Their CEO also came to see our plant not long ago. And if that turns out favorably, then probably starting next quarter we could have one more private-sector loop company added to our roster.
What type of growth are you observing in this segment looking ahead, say, one or two years out, or are we seeing that?
My inclination is to view it as fairly flat, or with expansion among private-sector lube companies tied directly to Baltech, since the public sector at present is entirely. Going forward, I doubt we'll be in a position to compete or engage in that sort of pricing battle. So we'll likely remain outside it unless an opportunity arises. With that said, I would be. Neutral regarding lube growth. It should return to 2 to 3% yearly expansion. That's what typically happens with the private players.
Got it. To follow up on what I asked earlier about PAT and EBITDA growth — you said PAD would be in line with the roughly 20% levels. So we'd expect depreciation to be at a similar level too, around 20% to 25%, as it is right now. So when could we see depreciation coming down, or will it stay at similar levels? Or is there something — as you said, capex will be significantly low next year — so another year after that, can depreciation come off, or will it be around at similar levels?
I'd say for another couple of years, depreciation will remain elevated, given how much capex we undertook across the last four years. It might ease off from here, since next year it should be roughly 80 crores, and I expect that going forward it will match depreciation, which comes to nearly 70 crores — 65 to 70 crores annually. Right now it's sitting at about 15 lakh crores each quarter. So roughly 60 — I think it's climbing at the moment. It could hold near that level, or perhaps a bit above it, through the next one year, and after that it should begin to decline, or at minimum level off where it is.
Got it. All right, thanks, sir.
When we get to that point, PAT growth should outpace EBITDA growth, probably. Rather than 20%, if EBITDA rises 20%, PAT could rise about 25%. Then obviously, if your depreciation drops off and that drops off, say two years from now. So at that stage, we could see higher PAD versus EBITDA. So this last question, could you share the utilization levels of your current capacity overall and by segment as well? Yeah. Okay. As I said, our total capacity utilization stands at roughly 67%. In Q3, I believe it's under 7% for sure. Hold on, let me tell you, it. It has now come down to about 62.5%. It was 74 in Q1, and it dropped to 62.5 across the last two quarters, and hopefully in Q4 it will exceed 70 plus. And next year, thanks to higher utilization of all ABG rate facilities, North Tinwal and QPAC, we hopefully remain above 70 for the entire next year.
Appreciate it, sir. That was the final question I had.
Thanks. Our following question comes from Deepak at Sundaram Mutual Fund. Go ahead.
Thanks for having me — can you hear me okay?
Yeah, yeah, yeah.
Hello, sir. Sir, I have a couple of questions. My first one concerns the MoU that we have signed with White Generation. Could you elaborate on what the commercial arrangement under this MoU is? And, let's say, what is the margin profile of these safety caps and closures? Also, when do we expect revenue from this arrangement to flow through into our P&L? And is it mostly related to, let's say, the pharma segment of these caps and closures? That is my first question.
No, it's mostly chemicals and lubricants. Oils, high-end chemicals, and lubricants too. So it's related to that. Not really connected to pharma. Maybe pharma chemicals, as they call them. Ingredients might use it, but not for pharma applications. It's also used in lubricants, though. And these caps and spouts are high value-add products. I'd guess at least the EBITDA range will be 80 to 100. Could be better, but volume pickup will be progressive. It won't happen overnight because the development time is longer. Their patents need to be developed into pilot molds first. And once the pilot mold samples are approved, we have to go for commercial molds. So the first two products began pilot mould development. By the end of this month one product will be out, and the second month, probably end of March, we'll have both products — they're related products — ready by end of March. And once we start marketing efforts by April, probably the commercial volumes can only go out in Q2. So from Q2, if the numbers start coming in, by the end of the year.
Looking at Q4 — actually Q3 and Q4 — we can already see some of this. Numbers are coming in, adding a few crores. That's just the start. Once the relationship is built and they develop confidence in us — they have multiple products to offer, and we're keen as well, since those products are quite challenging. They're also strong value-add products. Even for Indian applications, we're covered under the MoU. We can sell them in India provided we pay them a small amount. That lets us explore the Indian lubricant market, or the Indian chemical market, where some of them still import certain closures — not in large volumes, but it's growing in India. And if it goes into loops, the volumes are enormous. So the opportunity is solid. It does take a bit of time, though. And on value add, it's quite a good value add.
All right, so EBITDA per kg comes in at 80 to 100 rupees per kg. That's right.
At the very least.
All right. And sir, I just wanted to get a sense, as things stand right now, of how much of this product is import dependent and how much is catered to domestic manufacturer, and who would be our competitor here? Let's say from a local manufacturing point of view.
No, no, no. Right now nobody in India is producing this. They're using it heavily, they say, even within the lubricant industry. Our competitors are the current competitors. But this product that we're developing — once the details are fully out and we can demonstrate what it's capable of — it will definitely be a different ball game in terms of functionality, and that may give us good growth back. In the lubricant industry too, if they adopt it.
Alright, and so my last question is about the cost item. This quarter, other expenses dropped sharply by 8% quarter over quarter, and I just wanted to get a sense of what drove that. Was it a one-off, or is it a more sustainable figure as we move forward? What I mean is, in terms of operational efficiency.
These results are definitely the product of operational efficiencies. You'll keep seeing improvement there. What exactly do you mean by other expenses? Could you help me with that? What is it when other expenses come down? That's what he's saying. There are some power incentives debates. We got those. That may be what brought the other expenses down. And as I said, once the units are consolidated, inter-unit transfers will drop considerably. That also falls under other expenses.
Alright.
We're pursuing solar as well. An increasing number of solar facilities have been coming online. Every one of the units. With luck, by June or July, the majority of our units will be running on solar power. That will bring us savings too, as forecast, yes.
Thanks very much, sir, and best of luck.
Thank you. Before we move on to the next question, participants, please keep your questions to one per participant. We take the next question from the line of Deepak Saha from Nirmal Bounce Institutional Equities. Please go ahead.
Just one question from me. For the quarter, how would that break down between IML and non-IML?
Yeah, that's roughly 75% IML and HDL for labeling the containers, and 25% is non-IML plain or skill bidding.
Appreciate it.
Thanks. Our next question comes from Pratyush Damani, an individual investor. Go ahead.
Okay, many thanks, operator. And sir, one question I’m seeing here is that we have been paying dividends for the last three, four years, roughly 15, 20 crore each year. That works out to about 0.5% in dividend yield terms. But had that same dividend gone toward interest cost repayment, we might have saved 5, 6 crores in interest expense every year. That, in turn, would have added 1.2% to Roe. So could you explain once the rationale and the trade-off between distributing dividend and, like, paying down debt? Because I think shareholders could be somewhat happier with debt repayment, so that free cash flow and return on equity come out better for us.
Yes, we've acted on that suggestion from a range of investors—not just individuals, but funds as well. And if you look at the dividend outflow, it has dropped considerably over the last three years, both to safeguard the ROE and to bring down debt. So that same trend will carry on going forward too. So there's.
Alright, that’s fine. Thanks.
Thanks. Our next question comes from Chirag at Keynote Capital. Go ahead.
Thanks for taking the question — and thanks again for the chance to ask it. Sir, I have just one question. Looking at Ex Pharma over the past 8 quarters, across all 3 segments — food, Q pack, and drinks — and considering the view, what I can see is that our realization, or revenue per kg, has been trending downward this quarter. It sits at the lowest point of the last year. So I just wanted to understand: is some kind of raw material cost pass-through happening, or is competition what's affecting us?
There is a decrease in the overall cost per kg. I would agree with what you said regarding recent quarters, but when you examine our raw material cost, the mix is also declining. Raw material cost in Q1 stood at 94 rupees per kilogram, and it has decreased to 86.67 at present — nearly 8 rupees. Meanwhile, the sale price has fallen by roughly 9 rupees, so the difference is barely 1 rupee. Also, in Q1 our food and FMCG segment is typically at its highest as a share of sales relative to Q2 and Q3. Therefore, whenever the raw material or recipe cost decreases, we generally pass that along to clients in order to remain competitive. So we are not going beyond, in terms of our own approach, to the point of reducing our profitability. Otherwise we cannot maintain growth in EBITDA per kg. If you look at EBITDA per kg, for the 9 months last year it was 37.6, and this year for 9 months it is — last year's full year was 37.6, and this year's 9 months is 40.24. That is a clean 3 and a half rupees — you know, 2 and a half rupees — increase in EBITDA per kg. So that demonstrates the company's ability to.
Keep its margins intact even with competition.
I. I completely agree with the point that our EBITDA per kg is staying steady and trending upward. But if I’m not mistaken, during the previous conference call you said that you were encountering a certain amount of competitive intensity in the food segments. This is a follow-up question.
Sure — competition is definitely intensifying across every segment, no question about that. What keeps our clients with us is our capacity to deliver on time, not our pricing. The reason is that most food and FMCG companies have seasonal demand patterns, and when the season hits they need reliable service from packaging suppliers. So they can't really place their bets on just anyone — someone with two or three robots running a handful of product lines — when they can compare that to Maltech, which has over 120 robos and 200 injection model emissions across 10 plants in India. So our ability to serve them is clearly stronger. That said, last year our printing capacities were somewhat misplanned. So going forward, losing a client may happen very rarely. We do certainly lose one here and there, but we're also able to add new ones much faster.
Thanks a lot, Lasmandu.
Thank you, ladies and gentlemen. Because of time limits, we’ll treat that as today’s final question, and at this point we’d like to turn the conference back to management for closing remarks. Sir, over to you.
Thank you so much to everyone who took part and stayed engaged in our investor meet for the third quarter results. My thanks as well to MK Global for setting up this call, and thanks too to Anushka. Have a wonderful day, all of you. Bye. Thank you.
Appreciation is extended by MK Global Financial Services Limited. That brings this conference to a close. We’re grateful you took part, and at this point you can disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Mold-Tek Packaging Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Mold-Tek Packaging Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.